C12N 2310/3535
Nitrogen
C12N2310/3535 (Nitrogen) appears on 90 US grants and 95 published applications in this corpus.
Search patents in C12N- Granted patents
- 90
- Published applications
- 95
- Assignees
- 33
- Inventors
- 127
- Latest grant
- 15 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 5 | 0 |
| 1997 | 14 | 0 |
| 1998 | 12 | 0 |
| 1999 | 9 | 0 |
| 2000 | 8 | 0 |
| 2001 | 2 | 1 |
| 2002 | 11 | 2 |
| 2003 | 2 | 7 |
| 2004 | 0 | 2 |
| 2005 | 2 | 2 |
| 2006 | 1 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 3 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 2 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 8 |
| 2015 | 4 | 14 |
| 2016 | 6 | 3 |
| 2017 | 1 | 6 |
| 2018 | 1 | 5 |
| 2019 | 0 | 5 |
| 2020 | 0 | 6 |
| 2021 | 3 | 4 |
| 2022 | 0 | 6 |
| 2023 | 1 | 2 |
| 2024 | 1 | 4 |
| 2025 | 1 | 5 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Conjugated antisense compounds and their use15 Apr 2025US 12,275,940 B2Ionis Pharmaceuticals, Inc.
- Exon skipping compositions for treating muscular dystrophy19 Mar 2024US 11,932,851 B2Sarepta Therapeutics, Inc.
- Conjugated antisense compounds and their use15 Aug 2023US 11,725,208 B2Ionis Pharmaceuticals, Inc.
- Antisense nucleic acids6 Jul 2021US 11,053,497 B2National Center of Neurology and Psychiatry
- Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof6 Apr 2021US 10,968,452 B2Alnylam Pharmaceuticals, Inc.
- Antisense polynucleotides to induce exon skipping and method of treating dystrophies20 Aug 2026US 2026/0242792 A1The University of Chicago
- Antisense polynucleotides to induce exon skipping and method of treating dystrophies8 Jan 2026US 2026/0009033 A1The University of Chicago
- Conjugated Antisense Compounds and Their Use30 Oct 2025US 2025/0333741 A1Ionis Pharmaceuticals, Inc.
- Exon skipping compositions for treating muscular dystrophy24 Jul 2025US 2025/0236869 A1Sarepta Therapeutics, Inc.
- Antisense polynucleotides to induce exon skipping and method of treating dystrophies5 Jun 2025US 2025/0179495 A1The University of Chicago
Most cited
By later US patents
- 2'modified nucleoside and nucleotide compounds599US 5,466,786 AGilead Sciences, Inc. · 1995
- 2'deoxy-2'-alkylnucleotide containing nucleic acid521US 5,627,053 ARibozyme Pharmaceuticals, Inc. · 1997
- 2' Modified Oligonucleotides273US 5,792,847 AGilead Sciences, Inc. · 1998
- Methods and compositions involving miRNA and miRNA inhibitor molecules171US 9,506,061 B2Asuragen, Inc. · 2016
- 2′ Modified oligonucleotides166US 6,476,205 B1Isis Pharmaceuticals, Inc. · 2002